US House Appropriators Have Little Left To Say About Allowing Cannabinoids In Supplements

Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.

House appropriators add items to their list of nutritional product-related requests for the US Food and Drug Administration, repeat some and elaborate further on others but have comparatively little to say about the agency’s work on allowing the use of cannabinoids in dietary supplements.

The Appropriation Committee’s report accompanying legislation including the FDA’s fiscal year 2022 funding appears to signal that other than...